E
AIM ImmunoTech Inc.
AIM
$0.12
-$0.0034-2.76%
E
Sell
11/6/2024Downgrade
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 11/6/2024 due to a decline in the total return index, growth index and volatility index.
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 11/6/2024 due to a decline in the total return index, growth index and volatility index.
D
Sell
10/22/2024Upgraded
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 10/22/2024 due to an increase in the volatility index.
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 10/22/2024 due to an increase in the volatility index.
E
Sell
10/3/2024Downgrade
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 10/3/2024 due to a decline in the total return index and volatility index.
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 10/3/2024 due to a decline in the total return index and volatility index.
D
Sell
9/18/2024Upgraded
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 9/18/2024 due to an increase in the valuation index.
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 9/18/2024 due to an increase in the valuation index.
E
Sell
9/3/2024Downgrade
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 9/3/2024 due to a decline in the valuation index, volatility index and total return index.
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 9/3/2024 due to a decline in the valuation index, volatility index and total return index.
D
Sell
8/19/2024Upgraded
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 8/19/2024 due to an increase in the valuation index, growth index and total return index. Earnings per share increased from -$0.12 to -$0.0347, operating cash flow increased 37.53% from -$4.82M to -$3.01M, and EBIT increased 35.58% from -$5.73M to -$3.69M.
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 8/19/2024 due to an increase in the valuation index, growth index and total return index. Earnings per share increased from -$0.12 to -$0.0347, operating cash flow increased 37.53% from -$4.82M to -$3.01M, and EBIT increased 35.58% from -$5.73M to -$3.69M.
E
Sell
5/28/2024Downgrade
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 5/28/2024 due to a decline in the valuation index, solvency index and volatility index. Debt to equity increased from 0.02 to 0.68, and the quick ratio declined from 1.65 to 1.11.
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 5/28/2024 due to a decline in the valuation index, solvency index and volatility index. Debt to equity increased from 0.02 to 0.68, and the quick ratio declined from 1.65 to 1.11.
D
Sell
5/15/2024Upgraded
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 5/15/2024 due to an increase in the volatility index and total return index.
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 5/15/2024 due to an increase in the volatility index and total return index.
E
Sell
4/29/2024Downgrade
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 4/29/2024 due to a decline in the volatility index.
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 4/29/2024 due to a decline in the volatility index.
D
Sell
4/11/2024Upgraded
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 4/11/2024 due to an increase in the volatility index.
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 4/11/2024 due to an increase in the volatility index.
E
Sell
3/28/2024Downgrade
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 3/28/2024 due to a decline in the volatility index and total return index.
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 3/28/2024 due to a decline in the volatility index and total return index.
D
Sell
3/11/2024Upgraded
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 3/11/2024 due to an increase in the volatility index.
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 3/11/2024 due to an increase in the volatility index.
E
Sell
2/22/2024Downgrade
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 2/22/2024 due to a decline in the total return index and volatility index.
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 2/22/2024 due to a decline in the total return index and volatility index.
D
Sell
2/2/2024Upgraded
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 2/2/2024 due to an increase in the volatility index.
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 2/2/2024 due to an increase in the volatility index.
E
Sell
1/17/2024Downgrade
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 1/17/2024 due to a decline in the volatility index.
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 1/17/2024 due to a decline in the volatility index.
D
Sell
12/27/2023Upgraded
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 12/27/2023 due to an increase in the volatility index.
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 12/27/2023 due to an increase in the volatility index.
E
Sell
12/8/2023Downgrade
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 12/8/2023 due to a decline in the volatility index.
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 12/8/2023 due to a decline in the volatility index.
D
Sell
11/20/2023Upgraded
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 11/20/2023 due to an increase in the growth index, volatility index and total return index. Total revenue increased 9.52% from $42 to $46.
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 11/20/2023 due to an increase in the growth index, volatility index and total return index. Total revenue increased 9.52% from $42 to $46.
E
Sell
11/9/2023Downgrade
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 11/9/2023 due to a decline in the volatility index and growth index.
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 11/9/2023 due to a decline in the volatility index and growth index.
D
Sell
10/23/2023Upgraded
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 10/23/2023 due to an increase in the volatility index.
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 10/23/2023 due to an increase in the volatility index.
E
Sell
10/5/2023Downgrade
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 10/5/2023 due to a decline in the volatility index and total return index.
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 10/5/2023 due to a decline in the volatility index and total return index.
D
Sell
9/18/2023Upgraded
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 9/18/2023 due to an increase in the total return index, volatility index and valuation index.
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 9/18/2023 due to an increase in the total return index, volatility index and valuation index.
E
Sell
8/30/2023Downgrade
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 8/30/2023 due to a decline in the volatility index and valuation index.
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 8/30/2023 due to a decline in the volatility index and valuation index.
D
Sell
8/15/2023Upgraded
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 8/15/2023 due to an increase in the volatility index, total return index and valuation index.
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 8/15/2023 due to an increase in the volatility index, total return index and valuation index.
E
Sell
8/2/2023Downgrade
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 8/2/2023 due to a decline in the growth index and volatility index.
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 8/2/2023 due to a decline in the growth index and volatility index.
D
Sell
7/17/2023Upgraded
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 7/17/2023 due to an increase in the total return index and volatility index.
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 7/17/2023 due to an increase in the total return index and volatility index.
E
Sell
6/26/2023Downgrade
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 6/26/2023 due to a decline in the volatility index.
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 6/26/2023 due to a decline in the volatility index.
D
Sell
6/8/2023Upgraded
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 6/8/2023 due to an increase in the volatility index, growth index and total return index. Operating cash flow increased 39.36% from -$6.07M to -$3.68M, EBIT increased 22.7% from -$5.56M to -$4.3M, and earnings per share increased from -$0.0913 to -$0.0756.
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 6/8/2023 due to an increase in the volatility index, growth index and total return index. Operating cash flow increased 39.36% from -$6.07M to -$3.68M, EBIT increased 22.7% from -$5.56M to -$4.3M, and earnings per share increased from -$0.0913 to -$0.0756.
E
Sell
5/11/2023Downgrade
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 5/11/2023 due to a decline in the volatility index and total return index.
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 5/11/2023 due to a decline in the volatility index and total return index.
D
Sell
4/26/2023Upgraded
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 4/26/2023 due to an increase in the volatility index and total return index.
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 4/26/2023 due to an increase in the volatility index and total return index.
E
Sell
4/6/2023Downgrade
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 4/6/2023 due to a decline in the volatility index and solvency index.
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 4/6/2023 due to a decline in the volatility index and solvency index.
D
Sell
4/4/2023Upgraded
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 4/4/2023 due to an increase in the volatility index.
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 4/4/2023 due to an increase in the volatility index.
E
Sell
3/14/2023Downgrade
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 3/14/2023 due to a decline in the total return index.
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 3/14/2023 due to a decline in the total return index.
D
Sell
2/23/2023Upgraded
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 02/23/2023.
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 02/23/2023.
E
Sell
2/8/2023Downgrade
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 2/8/2023 due to a decline in the solvency index, total return index and growth index. Operating cash flow declined 114.79% from -$2.31M to -$4.97M, the quick ratio declined from 30.54 to 12.69, and EBIT declined 38.89% from -$4.7M to -$6.52M.
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 2/8/2023 due to a decline in the solvency index, total return index and growth index. Operating cash flow declined 114.79% from -$2.31M to -$4.97M, the quick ratio declined from 30.54 to 12.69, and EBIT declined 38.89% from -$4.7M to -$6.52M.
D
Sell
11/7/2022Downgrade
AIM ImmunoTech Inc. (AIM) was downgraded to D- from D on 11/7/2022 due to a noticeable decline in the solvency index and growth index. The quick ratio declined from 60.29 to 30.54, EBIT declined 48.95% from -$3.15M to -$4.7M, and earnings per share declined from -$0.0796 to -$0.101.
AIM ImmunoTech Inc. (AIM) was downgraded to D- from D on 11/7/2022 due to a noticeable decline in the solvency index and growth index. The quick ratio declined from 60.29 to 30.54, EBIT declined 48.95% from -$3.15M to -$4.7M, and earnings per share declined from -$0.0796 to -$0.101.
D
Sell
5/16/2022Upgraded
AIM ImmunoTech Inc. (AIM) was upgraded to D from E+ on 5/16/2022 due to an increase in the growth index, total return index and valuation index. Operating cash flow increased 51.99% from -$5.75M to -$2.76M, EBIT increased 44.37% from -$5.67M to -$3.15M, and earnings per share increased from -$0.1221 to -$0.0796.
AIM ImmunoTech Inc. (AIM) was upgraded to D from E+ on 5/16/2022 due to an increase in the growth index, total return index and valuation index. Operating cash flow increased 51.99% from -$5.75M to -$2.76M, EBIT increased 44.37% from -$5.67M to -$3.15M, and earnings per share increased from -$0.1221 to -$0.0796.
E
Sell
5/13/2022Downgrade
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
D
Sell
5/4/2022Upgraded
AIM ImmunoTech Inc. (AIM) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index and total return index.
AIM ImmunoTech Inc. (AIM) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index and total return index.
E
Sell
5/1/2022Downgrade
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
D
Sell
4/27/2022Upgraded
AIM ImmunoTech Inc. (AIM) was upgraded to D from E+ on 4/27/2022 due to an increase in the total return index.
AIM ImmunoTech Inc. (AIM) was upgraded to D from E+ on 4/27/2022 due to an increase in the total return index.
E
Sell
4/20/2022Downgrade
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 04/20/2022.
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 04/20/2022.
D
Sell
4/18/2022Downgrade
AIM ImmunoTech Inc. (AIM) was downgraded to D- from D on 4/18/2022 due to a major decline in the total return index, volatility index and solvency index.
AIM ImmunoTech Inc. (AIM) was downgraded to D- from D on 4/18/2022 due to a major decline in the total return index, volatility index and solvency index.
D
Sell
11/9/2021Upgraded
AIM ImmunoTech Inc. (AIM) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index.
AIM ImmunoTech Inc. (AIM) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index.
E
Sell
11/8/2021Downgrade
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D on 11/8/2021 due to a major decline in the growth index, volatility index and valuation index. Earnings per share declined from -$0.0783 to -$0.1228, and total revenue declined 17.86% from $28 to $23.
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D on 11/8/2021 due to a major decline in the growth index, volatility index and valuation index. Earnings per share declined from -$0.0783 to -$0.1228, and total revenue declined 17.86% from $28 to $23.
D
Sell
5/1/2020Upgraded
AIM ImmunoTech Inc. (AIM) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the total return index, volatility index and growth index. Earnings per share increased from -$1.1322 to -$0.1336, operating cash flow increased 10.02% from -$2.54M to -$2.29M, and EBIT increased 6.12% from -$3.21M to -$3.01M.
AIM ImmunoTech Inc. (AIM) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the total return index, volatility index and growth index. Earnings per share increased from -$1.1322 to -$0.1336, operating cash flow increased 10.02% from -$2.54M to -$2.29M, and EBIT increased 6.12% from -$3.21M to -$3.01M.
D
Sell
1/21/2020Upgraded
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 1/21/2020 due to a noticeable increase in the growth index, solvency index and efficiency index. Total revenue increased 110.34% from $29 to $61, total capital increased 81.5% from $11.44M to $20.76M, and the quick ratio increased from 1.68 to 2.81.
AIM ImmunoTech Inc. (AIM) was upgraded to D- from E+ on 1/21/2020 due to a noticeable increase in the growth index, solvency index and efficiency index. Total revenue increased 110.34% from $29 to $61, total capital increased 81.5% from $11.44M to $20.76M, and the quick ratio increased from 1.68 to 2.81.
E
Sell
9/18/2019Downgrade
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 9/18/2019 due to a decline in the volatility index and total return index.
AIM ImmunoTech Inc. (AIM) was downgraded to E+ from D- on 9/18/2019 due to a decline in the volatility index and total return index.
D
Sell
6/26/2019Upgraded
Hemispherx Biopharma, Inc. (HEB) was upgraded to D- from E+ on 6/26/2019 due to an increase in the valuation index and growth index.
Hemispherx Biopharma, Inc. (HEB) was upgraded to D- from E+ on 6/26/2019 due to an increase in the valuation index and growth index.
E
Sell
5/16/2019Downgrade
Hemispherx Biopharma, Inc. (HEB) was downgraded to E+ from D- on 5/16/2019 due to a noticeable decline in the solvency index, growth index and valuation index. Earnings per share declined from -$0.0331 to -$0.07, and EBIT declined 11.68% from -$2.62M to -$2.93M.
Hemispherx Biopharma, Inc. (HEB) was downgraded to E+ from D- on 5/16/2019 due to a noticeable decline in the solvency index, growth index and valuation index. Earnings per share declined from -$0.0331 to -$0.07, and EBIT declined 11.68% from -$2.62M to -$2.93M.
D
Sell
3/11/2016Downgrade
Hemispherx Biopharma, Inc. (HEB) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and growth index. Total revenue declined 51.06% from $47 to $23.
Hemispherx Biopharma, Inc. (HEB) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and growth index. Total revenue declined 51.06% from $47 to $23.
D
Sell
3/14/2014Downgrade
Hemispherx Biopharma, Inc. (HEB) was downgraded to D from D+ on 3/14/2014 due to a decline in the efficiency index, solvency index and valuation index. Net income declined 37.79% from -$5.14M to -$3.2M, and total capital declined 25.25% from $39.27M to $29.35M.
Hemispherx Biopharma, Inc. (HEB) was downgraded to D from D+ on 3/14/2014 due to a decline in the efficiency index, solvency index and valuation index. Net income declined 37.79% from -$5.14M to -$3.2M, and total capital declined 25.25% from $39.27M to $29.35M.
AMEX
03/13/2025 4:00PM Eastern
Quotes delayed
